226 related articles for article (PubMed ID: 24058100)
1. [Diagnosis and treatment options of neuroendocrine tumours].
Uhlyarik A; Pápai Z
Orv Hetil; 2013 Sep; 154(39):1549-55. PubMed ID: 24058100
[TBL] [Abstract][Full Text] [Related]
2. [Neuroendocrine tumours of the gastrointestinal tract].
Plöckinger U; Wiedenmann B
Z Gastroenterol; 2004 Jun; 42(6):517-27. PubMed ID: 15190448
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine gastrointestinal tumours.
Oberg K
Ann Oncol; 1996 Jul; 7(5):453-63. PubMed ID: 8839899
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic neuroendocrine neoplasms.
Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
[TBL] [Abstract][Full Text] [Related]
6. [Carcinoid tumors].
Pregun I; Bodoky G; Rácz K; Tulassay Z
Orv Hetil; 2010 Nov; 151(46):1885-94. PubMed ID: 21044939
[TBL] [Abstract][Full Text] [Related]
7. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours.
Nikou GC; Marinou K; Thomakos P; Papageorgiou D; Sanzanidis V; Nikolaou P; Kosmidis C; Moulakakis A; Mallas E
Pancreatology; 2008; 8(4-5):510-9. PubMed ID: 18765956
[TBL] [Abstract][Full Text] [Related]
8. [Significance of biochemical markers in the diagnosis of neuroendocrine tumours and for the follow-up of patients].
Tőke J; Czirják G; Tóth M; Rácz K; Patócs A
Orv Hetil; 2014 Nov; 155(45):1775-82. PubMed ID: 25362640
[TBL] [Abstract][Full Text] [Related]
9. Bone metastases in neuroendocrine tumors.
Zamborsky R; Svec A; Kokavec M; Galbavy S
Bratisl Lek Listy; 2017; 118(9):529-534. PubMed ID: 29061059
[TBL] [Abstract][Full Text] [Related]
10. GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers.
Verbeek WH; Korse CM; Tesselaar ME
Eur J Endocrinol; 2016 Jan; 174(1):R1-7. PubMed ID: 26162406
[TBL] [Abstract][Full Text] [Related]
11. Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE).
Corleto VD; Panzuto F; Falconi M; Cannizzaro R; Angeletti S; Moretti A; Delle Fave G; Farinati F;
Dig Liver Dis; 2001 Apr; 33(3):217-21. PubMed ID: 11407665
[TBL] [Abstract][Full Text] [Related]
12. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.
Janson ET; Sørbye H; Welin S; Federspiel B; Grønbaek H; Hellman P; Mathisen O; Mortensen J; Sundin A; Thiis-Evensen E; Välimäki MJ; Oberg K; Knigge U
Acta Oncol; 2010 Aug; 49(6):740-56. PubMed ID: 20553100
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
14. Tumour markers in neuroendocrine tumours.
Oberg K; Janson ET; Eriksson B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S160-2. PubMed ID: 10604122
[TBL] [Abstract][Full Text] [Related]
15. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
[TBL] [Abstract][Full Text] [Related]
16. Commentary to "chromogranin a: biological function and clinical utility in neuroendocrine tumor disease".
Jeske W; Glinicki P; Kapuścińska R
Ann Surg Oncol; 2011 Jan; 18(1):293. PubMed ID: 20549561
[No Abstract] [Full Text] [Related]
17. [Management of treatment in patients with neuroendocrine neoplasmas of digestive tract].
Kinová S; Kovácová M; Caprnda M; Koren M
Vnitr Lek; 2015 Dec; 61(12 Suppl 5):5S12-20. PubMed ID: 27124967
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.
Marotta V; Zatelli MC; Sciammarella C; Ambrosio MR; Bondanelli M; Colao A; Faggiano A
Endocr Relat Cancer; 2018 Jan; 25(1):R11-R29. PubMed ID: 29066503
[TBL] [Abstract][Full Text] [Related]
19. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F
Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104
[TBL] [Abstract][Full Text] [Related]
20. Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy.
Soeiro P; Martins H; Silva R; Moreira AP
BMJ Case Rep; 2020 Mar; 13(3):. PubMed ID: 32234855
[No Abstract] [Full Text] [Related]
[Next] [New Search]
